Company intelligence / Profile preview

Channel Medsystems

Berkeley, California, United Statescerene.com ↗

Ownership: Private
Employees: ~16
Development stage: Commercial

Overview

Channel Medsystems has developed and commercialized the Cerene Cryotherapy Device for in-office endometrial ablation to treat heavy menstrual bleeding. The device is FDA-approved and supported by significant long-term clinical data demonstrating safety and effectiveness. It offers a minimally invasive alternative that preserves access to the uterine cavity for future diagnostic evaluations and does not require general anesthesia.

Therapeutic areas: Women's Health
Modalities: DeviceCryotherapy device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

Cerene

Commercial

Indications: Heavy menstrual bleeding

Partnerships

Mayumana Healthcare B.V. (exclusive distribution rights for Cerene in the Netherlands)

Beyond the preview

Go deeper on Channel Medsystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Channel Medsystems.

Explore the full profile